NCT03291418View on ClinicalTrials.gov

To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

March 31, 2018

Study Completion Date

April 30, 2018

Conditions
Gastric Ulcer
Interventions
DRUG

ATB-346 OR Placebo

Comparison of gastrointestinal effects

DRUG

Naproxen sodium

Comparison of gastrointestinal effects

Trial Locations (1)

M9C 4Z5

Topstone Clinical Research, Toronto

Sponsors
All Listed Sponsors
lead

Antibe Therapeutics Inc.

INDUSTRY

NCT03291418 - To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects | Biotech Hunter | Biotech Hunter